Using machine learning to predict nerve damage from chemotherapy
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-10866528
This study is looking at how to predict and understand the painful nerve damage that can happen from chemotherapy in cancer patients, especially those with breast and colorectal cancers, so that doctors and patients can make better treatment choices together.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10866528 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding and predicting chemotherapy-induced peripheral neuropathy (CIPN), a painful condition affecting many cancer patients. By analyzing data from over 8,500 adults diagnosed with breast and colorectal cancers, the study aims to develop machine learning models that can accurately assess the risk of severe and chronic CIPN. The research will also explore how patients and healthcare providers can use this risk information to make informed treatment decisions. This approach seeks to improve patient outcomes by minimizing the impact of CIPN on cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 18 and older who are diagnosed with invasive breast or colorectal cancers and are receiving adjuvant chemotherapy.
Not a fit: Patients who are not undergoing chemotherapy or those with non-invasive cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help identify patients at high risk for CIPN, allowing for tailored treatment plans that minimize nerve damage and improve quality of life.
How similar studies have performed: Previous research has shown moderate success in developing risk models for CIPN, but this study aims to enhance predictive accuracy and validate these models in a larger, more diverse population.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ADAMS, ALYCE SOPHIA — STANFORD UNIVERSITY
- Study coordinator: ADAMS, ALYCE SOPHIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers